Trial Profile
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Erdheim-Chester disease
- Focus Therapeutic Use
- Acronyms LOVE
- 10 Aug 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016.
- 15 May 2014 New trial record